Factors Influencing Long Term Survival in Metastatic Castration Resistant Prostate Cancer Patients a Spanish Multicentre Experience

O Fernández Calvo, R C à lvarez Llosa, T Alonso Gordoa, N Láinez, à Rodríguez Sánchez, G De Velasco, U Anido, R García Marrero, E Martínez Ortega, A Viana, C Caballero Diaz, J García Sánchez, F Zambrana Tevar, à Pinto Marín, R Lastra, A Rodríguez, C Perezagua, à Gaizka Montesa, S Maciá and S Vázquez Estévez
Additional contact information
R C Ã lvarez Llosa: Complejo Hospitalario Universitario Ourense, Ourense, Spain
T Alonso Gordoa: Hospital Universitario Ramón y Cajal, Madrid, Spainia
N Láinez: Complejo Hospitalario de Navarra, Pamplona, Spain
à Rodríguez Sánchez: Complejo Asistencial Universitario de León, León, Spain
G De Velasco: Hospital Universitario 12 De Octubre, Madrid, Spain
U Anido: Hospital Clínico Universitario de Santiago de Compostela, Santiago De Compostela, Spain
R García Marrero: Hospital Universitario Tenerife, Tenerife, Spain
E Martínez Ortega: Hospital Universitario de Jaén, Jaén, Spain
A Viana: Hospital Nuestra Señora del Prado, Talavera De La Reina, Spain
C Caballero Diaz: Hospital General Universitario Valencia, Valencia, Spain
J García Sánchez: Hospital Arnau de Vilanova, Valencia, Spain
F Zambrana Tevar: Hospital Infanta Sofía, San Sebastián De Los Reyes, Spain
à Pinto Marín: Hospital Universitario La Paz, Madrid, Spain
R Lastra: Hospital San Jorge, Huesca, Spain
A Rodríguez: Hospital General de La Palma, Spain
C Perezagua: Hospital de Henares, Coslada, Madrid, Spain
à Gaizka Montesa: Hospital Carlos Haya, Málags, Spain
S Maciá: ICON Clinical Research, Alicante, Spain
S Vázquez Estévez: Hospital Universitario Lucus Augusti, Lugo, Spain

Cancer Therapy & Oncology International Journal, 2020, vol. 16, issue 1, 1-8

Abstract: Cabazitaxel is approved as second line treatment for metastatic castration resistant prostate cancer (mCRPC) after docetaxel failure. However, it is difficult to establish which patients will reach benefit. In this study, we aimed to analyze retrospectively clinical characteristics for cabazitaxel long responding mCRPC patients.

Keywords: juniper publishers:oncology journals; oncology research journals; oncology journal articles; oncology and cancer case reports; oncology journal of clinical and experimental cancer research; open access; open access journals; Oncology International Journal; juniper publishers reivew (search for similar items in EconPapers)
Date: 2020
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://juniperpublishers.com/ctoij/pdf/CTOIJ.MS.ID.555926.pdf (application/pdf)
https://juniperpublishers.com/ctoij/CTOIJ.MS.ID.555926.php (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:adp:jctoij:v:16:y:2020:i:1:p:1-8

DOI: 10.19080/CTOIJ.2020.16.555926

Access Statistics for this article

Cancer Therapy & Oncology International Journal is currently edited by Sophia Mathis

More articles in Cancer Therapy & Oncology International Journal from Juniper Publishers Inc.
Bibliographic data for series maintained by Robert Thomas ().